Pretransplantation C-Peptide level predicts early posttransplantation diabetes mellitus and has an impact on survival after allogeneic stem cell transplantation.

Predicting posttransplantation diabetes mellitus by regulatory T-cell phenotype: implications for metabolic intervention to modulate alloreactivity. Blood (2012) 0.85

Metabolic Complications Precede Alloreactivity and are Characterized by Changes in ST2 Signaling. Biol Blood Marrow Transplant (2016) 0.77

How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT. Bone Marrow Transplant (2016) 0.75

Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood (2011) 4.45

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest (2010) 3.53

Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood (2007) 2.29

High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood (2006) 2.21

Clinical guide to ABO-incompatible allogeneic stem cell transplantation. Biol Blood Marrow Transplant (2013) 2.17

Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res (2011) 2.06

Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant (2013) 1.88

Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study. Biol Blood Marrow Transplant (2011) 1.88

Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Transplant (2013) 1.80

Proper inference from Simon's two-stage designs. Stat Med (2008) 1.75

First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant (2012) 1.74

Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood (2007) 1.61

Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood (2013) 1.54

DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy. Clin Cancer Res (2013) 1.54

The clinical impact of the radiology report in wheezing and nonwheezing febrile children: a survey of clinicians. Pediatr Radiol (2009) 1.54

Validation of measurement scales in ocular graft-versus-host disease. Ophthalmology (2011) 1.50

Gestational diabetes mellitus resulting from impaired beta-cell compensation in the absence of FoxM1, a novel downstream effector of placental lactogen. Diabetes (2009) 1.47

SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival. Clin Cancer Res (2012) 1.46

Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria. Biol Blood Marrow Transplant (2007) 1.44

Pharmacologic enhancement of rat skin flap survival with topical oleic acid. Plast Reconstr Surg (2004) 1.40

Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol (2007) 1.40

Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood (2005) 1.37

Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. Blood (2008) 1.31

DNA-dependent protein kinase is a molecular target for the development of noncytotoxic radiation-sensitizing drugs. Cancer Res (2005) 1.30

Multiple myeloma. J Natl Compr Canc Netw (2011) 1.28

Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease. Blood (2007) 1.28

Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies. Haematologica (2010) 1.27

VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer (2009) 1.24

Extramedullary relapses after allogeneic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome. Haematologica (2010) 1.23

Female long-term survivors after allogeneic hematopoietic stem cell transplantation: evaluation and management. Semin Hematol (2012) 1.22

Allogeneic stem cell transplantation for myelodysplastic syndrome. Semin Hematol (2008) 1.18

Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma. Cancer (2005) 1.16

Multiple myeloma, version 1.2013. J Natl Compr Canc Netw (2013) 1.14

Donor KIR Genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies. Biol Blood Marrow Transplant (2010) 1.14

Pregnancy after hematopoietic cell transplantation: a report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant (2010) 1.11

Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen. J Thorac Oncol (2009) 1.10

Dyslipidemia after allogeneic hematopoietic stem cell transplantation: evaluation and management. Blood (2010) 1.08

HOXA11 is critical for development and maintenance of uterosacral ligaments and deficient in pelvic prolapse. J Clin Invest (2008) 1.07

Necrotising enterocolitis is characterised by disrupted immune regulation and diminished mucosal regulatory (FOXP3)/effector (CD4, CD8) T cell ratios. Gut (2012) 1.06

Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299. Proc Natl Acad Sci U S A (2005) 1.06

Characterizing tumor response to chemotherapy at various length scales using temporal diffusion spectroscopy. PLoS One (2012) 1.05

Shared gene expression profiles in individuals with autoimmune disease and unaffected first-degree relatives of individuals with autoimmune disease. Hum Mol Genet (2005) 1.04

Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients. Biol Blood Marrow Transplant (2010) 1.04

Smoking-related genomic signatures in non-small cell lung cancer. Am J Respir Crit Care Med (2008) 1.03

Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. Blood (2012) 1.03

Fruit and vegetable intakes are associated with lower risk of colorectal adenomas. J Nutr (2008) 1.01

T-cell depleted peripheral blood stem cell allotransplantation with T-cell add-back for patients with hematological malignancies: effect of chronic GVHD on outcome. Biol Blood Marrow Transplant (2006) 1.00

Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. J Clin Oncol (2013) 0.98

Time to explore preventive and novel therapies for bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2012) 0.98

High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects. Blood (2007) 0.97

Favorable outcomes in patients surviving 5 or more years after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant (2010) 0.95

Interactions of the p53 protein family in cellular stress response in gastrointestinal tumors. Mol Cancer Ther (2010) 0.94

Selectively T cell-depleted allografts from HLA-matched sibling donors followed by low-dose posttransplantation immunosuppression to improve transplantation outcome in patients with hematologic malignancies. Biol Blood Marrow Transplant (2011) 0.94

Cytomegalovirus ventriculoencephalitis in a peripheral blood stem cell transplant recipient. Clin Infect Dis (2006) 0.94

Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. Biol Blood Marrow Transplant (2013) 0.93

Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant (2013) 0.92

Tissue-specific regulatory T cells: biomarker for acute graft-vs-host disease and survival. Exp Hematol (2012) 0.92

Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib. Blood (2008) 0.92

The role of nutrition and effects on the cytokine milieu in allogeneic hematopoietic stem cell transplantation. Cell Immunol (2012) 0.92

Treatment options for transformed lymphoma: incorporating allogeneic stem cell transplantation in a multimodality approach. Biol Blood Marrow Transplant (2011) 0.92

AT-101, a pan-Bcl-2 inhibitor, leads to radiosensitization of non-small cell lung cancer. J Thorac Oncol (2010) 0.91

Cytoplasmic clusterin expression is associated with longer survival in patients with resected non small cell lung cancer. Cancer Epidemiol Biomarkers Prev (2007) 0.91

ATM polymorphism IVS62+60G>A is not associated with disease aggressiveness in prostate cancer. Urology (2006) 0.91

Extracorporeal photopheresis versus anticytokine therapy as a second-line treatment for steroid-refractory acute GVHD: a multicenter comparative analysis. Biol Blood Marrow Transplant (2013) 0.91

Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma. Cancer (2012) 0.90

Time to consider HPV vaccination after allogeneic stem cell transplantation. Biol Blood Marrow Transplant (2010) 0.90

Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer. BMC Syst Biol (2013) 0.89

Providing personalized prognostic information for adult leukemia survivors. Biol Blood Marrow Transplant (2013) 0.89

Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013. J Natl Compr Canc Netw (2012) 0.89

Prognostic factors for resected non-small cell lung cancer with pN2 status: implications for use of postoperative radiotherapy. Oncologist (2009) 0.89

Minimal residual disease in myeloma: are we there yet? Biol Blood Marrow Transplant (2012) 0.88

Thyroid abnormalities in patients treated with lenalidomide for hematological malignancies: results of a retrospective case review. Am J Hematol (2011) 0.87

Effects of bortezomib on the immune system: a focus on immune regulation. Biol Blood Marrow Transplant (2013) 0.87

Endocrine complications in long-term survivors after allogeneic stem cell transplant. Semin Hematol (2012) 0.86

Diabetes mellitus after hematopoietic stem cell transplantation. Endocr Pract (2010) 0.86

Efficacy of CD34+ stem cell dose in patients undergoing allogeneic peripheral blood stem cell transplantation after total body irradiation. Biol Blood Marrow Transplant (2007) 0.86

Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update. Expert Rev Hematol (2013) 0.86

Expression of CD30 in patients with acute graft-versus-host disease. Blood (2012) 0.85

Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotherapy. Cancer Immunol Immunother (2011) 0.85

Consolidative therapy with stem cell transplantation improves survival of patients with mantle cell lymphoma after any induction regimen. Exp Hematol (2012) 0.85

Genetic variation in recipient B-cell activating factor modulates phenotype of GVHD. Blood (2011) 0.85

Recovery of spermatogenesis after total-body irradiation. Blood (2006) 0.85

Predicting posttransplantation diabetes mellitus by regulatory T-cell phenotype: implications for metabolic intervention to modulate alloreactivity. Blood (2012) 0.85

Loss of polymeric immunoglobulin receptor expression is associated with lung tumourigenesis. Eur Respir J (2011) 0.84

Discontinuing nasal steroids might lower intraocular pressure in glaucoma. J Allergy Clin Immunol (2005) 0.84

Peripheral T-cell lymphomas: clinical features and prognostic factors of 92 cases defined by the revised European American lymphoma classification. Leuk Lymphoma (2003) 0.84

Vitamin D deficiency, autoimmunity, and graft-versus-host-disease risk: Implication for preventive therapy. Exp Hematol (2012) 0.84